11-dehydro-TXB2

11-dehydro-txb2 is a lipid of Fatty Acyls (FA) class. 11-dehydro-txb2 is associated with abnormalities such as endothelial dysfunction, Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis and Chronic ischemic heart disease NOS. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and Lipid Peroxidation. The associated genes with 11-dehydro-TXB2 are PTGS2 gene.

Cross Reference

Introduction

To understand associated biological information of 11-dehydro-TXB2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 11-dehydro-TXB2?

11-dehydro-TXB2 is suspected in endothelial dysfunction, Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 11-dehydro-TXB2

MeSH term MeSH ID Detail
Diabetes Mellitus D003920 90 associated lipids
Inflammation D007249 119 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Asthma D001249 52 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Thrombosis D013927 49 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Brain Ischemia D002545 89 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Polycythemia Vera D011087 13 associated lipids
Hyperlipidemias D006949 73 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Albuminuria D000419 18 associated lipids
Renal Artery Obstruction D012078 8 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Atherosclerosis D050197 85 associated lipids
Death, Sudden, Cardiac D016757 12 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Per page 10 20 | Total 20

PubChem Associated disorders and diseases

What pathways are associated with 11-dehydro-TXB2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 11-dehydro-TXB2?

There are no associated biomedical information in the current reference collection.

What functions are associated with 11-dehydro-TXB2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 11-dehydro-TXB2?

There are no associated biomedical information in the current reference collection.

What genes are associated with 11-dehydro-TXB2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 11-dehydro-TXB2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 11-dehydro-TXB2

Download all related citations
Per page 10 20 50 100 | Total 289
Authors Title Published Journal PubMed Link
pmid:27137142
pmid:28911508
pmid:28139223
pmid:27693274
pmid:26385032
pmid:24126290
pmid:25759102
pmid:27815971
pmid:27784132
pmid:25589198
pmid:25466142
pmid:28005558
pmid:24803308
pmid:24763965
pmid:27389698
pmid:27769511
pmid:25288566
pmid:25808116
pmid:24907931
pmid:27609361
pmid:27481134
pmid:27237049
pmid:27098431
pmid:25669623
pmid:26095809
pmid:
Fitzgerald DJ et al. Platelet activation in unstable coronary disease. 1986 N. Engl. J. Med. pmid:3531859
Lawson JA et al. Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. 1986 Anal. Biochem. pmid:3087234
Catella F et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. 1986 Proc. Natl. Acad. Sci. U.S.A. pmid:3461463
Westlund P et al. Identification of 11-dehydro-TXB2 as a suitable parameter for monitoring thromboxane production in the human. 1986 Prostaglandins pmid:3755250
Kumlin M and Granström E Radioimmunoassay for 11-dehydro-TXB2: a method for monitoring thromboxane production in vivo. 1986 Prostaglandins pmid:3823488
Westlund P et al. Circulating and urinary thromboxane B2 metabolites in the rabbit: 11-dehydro-thromboxane B2 as parameter of thromboxane production. 1986 Prostaglandins pmid:3520685
Schweer H et al. Tandem mass spectrometric determination of 11-dehydrothromboxane B2, an index metabolite of thromboxane B2 in plasma and urine. 1987 Anal. Biochem. pmid:3674365
Fitzgerald DJ et al. Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets. 1987 Am. J. Obstet. Gynecol. pmid:3618681
Ciabattoni G et al. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. 1987 Biochim. Biophys. Acta pmid:3567215
Alessandrini P et al. Thromboxane biosynthesis and platelet function in type I diabetes mellitus. 1988 N. Engl. J. Med. pmid:3292913
Seyberth HW et al. Excretion of primary prostanoids and their metabolites during acute volume expansion. 1988 Prostaglandins pmid:3163156
Lupinetti MD et al. Thromboxane biosynthesis in allergen-induced bronchospasm. Evidence for platelet activation. 1989 Am. Rev. Respir. Dis. pmid:2508524
Lorenz R et al. A new method using simple solid phase extraction for the rapid gas-chromatographic mass-spectrometric determination of 11-dehydro-thromboxane B2 in urine. 1989 Prostaglandins pmid:2772221
Ciabattoni G et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. 1989 Biochim. Biophys. Acta pmid:2752040
Patrignani P et al. Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey. 1989 Biochim. Biophys. Acta pmid:2752041
Lorenz RL et al. A critical evaluation of urinary immunoreactive thromboxane: feasibility of its determination as a potential vascular risk indicator. 1989 Biochim. Biophys. Acta pmid:2597697
Davì G et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. 1990 N. Engl. J. Med. pmid:2345567
Fitzgerald DJ et al. Thromboxane A2 synthesis in pregnancy-induced hypertension. 1990 Lancet pmid:1969511
Urinary thromboxane metabolites in pre-eclampsia. 1990 Lancet pmid:1971907
Wu P et al. Purification and characterization of an NAD(+)-dependent dehydrogenase that catalyzes the oxidation of thromboxane B2 at C-11 from porcine liver. Development and application of 11-dehydro-thromboxane B2 radioimmunoassay to enzyme assay. 1990 Biochim. Biophys. Acta pmid:2223826
Tönshoff B et al. Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. 1990 Kidney Int. pmid:2111418
Ciabattoni G et al. Radioimmunoassay of 11-dehydrothromboxane B2. 1990 Meth. Enzymol. pmid:2233352
Hayashi Y et al. Immunoaffinity purification of 11-dehydro-thromboxane B2 from human urine and plasma for quantitative analysis by radioimmunoassay. 1990 Anal. Biochem. pmid:2372112
Satoh K et al. Plasma 11-dehydrothromboxane B2: a reliable indicator of platelet hyperfunction in patients with ischemic stroke. 1991 Acta Neurol. Scand. pmid:2017905
Nagase T et al. Intravenous bolus of prednisolone decreases 15-hydroxyeicosatetraenoic acid formation in the rat model of acid aspiration. 1991 Crit. Care Med. pmid:2055084
Bridges AB et al. Circadian variation of endothelial cell function, red blood cell deformability and dehydro-thromboxane B2 in healthy volunteers. 1991 Blood Coagul. Fibrinolysis pmid:1932530
Van Geet C et al. Possible platelet contribution to pathogenesis of transient neonatal hyperammonaemia syndrome. 1991 Lancet pmid:1670726
Takayama K et al. Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. 1991 Jul-Sep ASAIO Trans pmid:1836334
Landolfi R et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. 1992 Blood pmid:1327286
Christman BW et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. 1992 N. Engl. J. Med. pmid:1603138
Tohgi H et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. 1992 Stroke pmid:1412574
Kumlin M et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. 1992 Am. Rev. Respir. Dis. pmid:1320824
Leonhardt A et al. Reference intervals and developmental changes in urinary prostanoid excretion in healthy newborns, infants and children. 1992 Acta Paediatr. pmid:1511190
Katoh K Possible relevance of lipid peroxidation and thromboxane production to the initiation and/or evolution of microangiopathy in non-hyperlipidemic type 2 diabetes mellitus. 1992 Diabetes Res. Clin. Pract. pmid:1478157
Reinke M Monitoring thromboxane in body fluids: a specific ELISA for 11-dehydrothromboxane B2 using a monoclonal antibody. 1992 Am. J. Physiol. pmid:1590375
Uyama O et al. Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. 1992 Intern. Med. pmid:1392173
Riutta A et al. Solid-phase extraction of urinary 11-dehydrothromboxane B2 for reliable determination with radioimmunoassay. 1992 Anal. Biochem. pmid:1519756
Lin JS et al. The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence. 1992 J. Urol. pmid:1635125
Rebuzzi AG et al. Importance of reperfusion on thromboxane A2 metabolite excretion after thrombolysis. 1992 Am. Heart J. pmid:1539506
Takasaki W et al. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor. 1993 Thromb. Res. pmid:8367836
Schiff E et al. Reduction of thromboxane A2 synthesis in pregnancy by polyunsaturated fatty acid supplements. 1993 Am. J. Obstet. Gynecol. pmid:8420313
Van Assche FA et al. Increased thromboxane formation in diabetic pregnancy as a possible contributor to preeclampsia. 1993 Am. J. Obstet. Gynecol. pmid:8420355
Koudstaal PJ et al. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. 1993 Stroke pmid:8421822
Ciabattoni G et al. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. 1993 J. Am. Coll. Cardiol. pmid:8473644
Foulon I et al. Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. 1993 Arterioscler. Thromb. pmid:8443146
Chen HI et al. Effects of exercise training on the biosynthesis of prostacyclin and thromboxane in rats. 1993 Acta Physiol. Scand. pmid:8452036
Benowitz NL et al. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. 1993 J. Am. Coll. Cardiol. pmid:7691912
Yasu T et al. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris. 1993 Am. J. Cardiol. pmid:8480641
Yamanaka S et al. 11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. 1993 Prostaglandins pmid:8484010
Smith SR et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. 1993 Transplantation pmid:8279014
Djurup R et al. Rapid, direct enzyme immunoassay of 11-keto-thromboxane B2 in urine, validated by immunoaffinity/gas chromatography-mass spectrometry. 1993 Clin. Chem. pmid:8252718
Chiabrando C et al. Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B2 in man. 1993 Prostaglandins pmid:8321910
Kitano A et al. Increased 11-dehydrothromboxane B2 in migraine: platelet hyperfunction in patients with migraine during headache-free period. 1994 Headache pmid:8002323
Pape HC et al. Does the reamer type influence the degree of lung dysfunction after femoral nailing following severe trauma? An animal study. 1994 J Orthop Trauma pmid:7965291
Wallén NH et al. Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris. 1994 Br J Clin Pharmacol pmid:7946939
Jörres A et al. Urinary excretion of thromboxane and markers for renal injury in patients undergoing cardiopulmonary bypass. 1994 Artif Organs pmid:7527629
van Kooten F et al. Evidence for episodic platelet activation in acute ischemic stroke. 1994 Stroke pmid:8303731
Larsson PT et al. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. 1994 Circulation pmid:8181117
Foegh ML et al. Urinary thromboxane A2 metabolites in patients presenting in the emergency room with acute chest pain. 1994 J. Intern. Med. pmid:8308478
Chiabrando C et al. Urinary excretion of 2,3-dinor-thromboxane B1, a major metabolite of thromboxane B2 in the rat. 1994 Prostaglandins pmid:7938613
Kawamura M et al. Evaluation of plasma 11-dehydro-thromboxane B2 as an indicator for thromboxane A2 synthesis in vivo in laboratory animals. 1995 Thromb. Res. pmid:7778061
Cipollone F et al. Effects of nabumetone on prostanoid biosynthesis in humans. 1995 Clin. Pharmacol. Ther. pmid:7554708
Schlit AF et al. Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives. 1995 Contraception pmid:7750285
Ferretti A and Flanagan VP Mass spectrometric evidence for the anomalous chemical behavior of 11-dehydrothromboxane B2. 1995 Chem. Phys. Lipids pmid:7586090
Milani M et al. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. 1995 Am. J. Cardiol. pmid:7604798
Laffi G et al. Defective aggregation in cirrhosis is independent of in vivo platelet activation. 1996 J. Hepatol. pmid:8738730
Stein CM et al. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. 1996 Arthritis Rheum. pmid:8670323
Cuiper LL et al. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. 1996 J. Appl. Physiol. pmid:8847301
Schaefer WR et al. Urinary excretion of 2,3-dinor-6-keto-PGF1 alpha and 11-dehydro-TXB2 by the gravid spontaneously hypertensive rat. 1996 Prostaglandins pmid:8875634
Reilly M et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. 1996 Circulation pmid:8964113
Milani M et al. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia. 1996 Biomed. Pharmacother. pmid:8952866
Lahoz C et al. Effects of dietary fat saturation on eicosanoid production, platelet aggregation and blood pressure. 1997 Eur. J. Clin. Invest. pmid:9352251
Farker K et al. Measurements of urinary prostaglandins in young ovulatory women during the menstrual cycle and in postmenopausal women. 1997 Prostaglandins pmid:9373880
Davì G et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. 1997 Am. J. Respir. Crit. Care Med. pmid:9412557